Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | CLPP | Q16740 | 6/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767848 | 1.00 | KMT2A (0.53) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL4077130 | 0.90 | SIGMAR1 (0.49) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL1549990 | 0.89 | KMT2A (0.51) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL2532723 | 0.87 | SIGMAR1 (0.43) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL1911808 | 0.84 | KMT2A (0.52) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL1911807 | 0.84 | KMT2A (0.52) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL2868214 | 0.84 | KMT2A (0.59) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL14872729 | 0.84 | KMT2A (0.52) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL11947240 | 0.81 | KMT2A (0.49) | KMT2AMEN1C5AR1PNMTKDM4E | |
| SCHEMBL998652 | 0.81 | C5AR1 (0.68) | KMT2AMEN1C5AR1PNMTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-3630116-B1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINE INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117534672-A | New preparation method of APDS (active pharmaceutical ingredient) therapeutic drug | 北京康立生医药技术开发有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-08-18 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-24 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1885369-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | EVOTEC SE (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | KMT2A 2743/4885MEN1 2254/4885C5AR1 2620/4885 |
| US-20060258689-A1 | 2,3-Difluoro-benzyl)-[6-(5-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-yl]-amine, useful for the prevention and treatment of pain, inflammation, cognitive disorders, anxiety and depression in humans | BDNF, OPRL1, GRIN2D | KMT2A 1221/4885MEN1 4034/4885C5AR1 280/4885 |
| US-10421765-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KMT2A 1160/4885MEN1 3160/4885C5AR1 3901/4885 |
| US-10745420-B2 | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | ATR, DTYMK, CHEK1 | KMT2A 1160/4885MEN1 3160/4885C5AR1 3901/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | KMT2A 2734/4885MEN1 2822/4885C5AR1 132/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | KMT2A 2743/4885MEN1 2254/4885C5AR1 2620/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | KMT2A 2743/4885MEN1 2254/4885C5AR1 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.